Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
November 22 2022 - 6:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that Jay R. Luly, Ph.D.,
President and Chief Executive Officer, will participate in two
investor conferences being webcast in November:
- Piper Sandler 34th Annual Healthcare Conference: Fireside Chat
at 2:00 p.m. ET on November 29
- Evercore ISI 5th Annual HealthCONx Conference: Fireside Chat at
3:30 p.m. ET on November 30
A live webcast of each event will be accessible by visiting
under "Events & Presentations" in the investors section of
Enanta’s at www.enanta.com. Replays of the webcasts will be
available following the presentations and will be archived for
approximately 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates in development for the following disease
targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19)
and hepatitis B virus (HBV). Enanta is also conducting research in
human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is part of one of the leading treatment
regimens for curing chronic HCV infection and is sold by AbbVie in
numerous countries under the tradenames MAVYRET® (U.S.) and
MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221122005191/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024